Mersana Therapeutics Appoints Andrew A. F. Hack, M.D., Ph. D. to Board of Directors
CAMBRIDGE, Mass., January 5, 2017 -- Mersana Therapeutics, Inc., a biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Fleximer® platform technology, today announced the appointment of Andrew A. F. Hack, M.D., Ph. D, to its board of directors.
“I am delighted to welcome Andrew to the Mersana Board of Directors. He brings a unique understanding of the interface of science, medicine, and the capital markets,” said Anna Protopapas, President and Chief Executive Officer of Mersana. “Andrew’s extensive experience in the biotechnology industry and his track record in building biotech companies that address important patient needs and deliver shareholder value will prove invaluable to Mersana as we continue to grow our pipeline and advance our lead products to the clinic.”
“Mersana has leveraged its highly-differentiated ADC platform to generate a compelling pipeline supported by impressive pre-clinical data. The Company has also built a strong foundation with top-tier investors, strategic partnerships, and a seasoned leadership team” said Dr. Hack. “I see tremendous potential and I look forward to working with Mersana to advance its pipeline for the benefit of cancer patients.”
Dr. Hack currently serves as Chief Financial Officer at Editas Medicine; a position he has held since 2015. Previously, he served as a portfolio manager at Millennium Management, managing a healthcare investment fund focused on biotechnology, pharmaceutical, and medical device companies. Prior to Millennium, Dr. Hack was a securities analyst at HealthCor Management, Carlyle-Blue Wave Partners, and the MPM BioEquities Fund. He started his investment career covering the biotechnology sector at Banc of America Securities. In addition, Andrew was a co-founder of Reify Corporation, a life science tools and drug discovery company.
Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D., was named the inaugural Frank Family Scholar, and received awards from the American Heart Association and the American Society for Cell Biology.
Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of immunoconjugates using our platforms
Stern Investor Relations, Inc.